TopGum Industries Ltd. posted first-quarter 2026 revenues of $31.9 million, an 85% year-over-year increase that marked the company's ninth consecutive record quarter versus the corresponding prior-year period — a streak that underscores sustained demand for functional gummy formats across the dietary supplement and functional food channels.
The dietary supplements segment drove the bulk of the headline figure, generating $25.8 million in Q1 revenues — a triple-digit gain of approximately 162% year over year — and now accounts for roughly 81% of total group revenues. Adjusted EBITDA surged 112% to $5.3 million, representing a 17% margin, up from approximately 15% in the year-ago quarter. The company's order backlog for the dietary supplements sector reached a record $52 million, covering the next four to five months of production, signaling near-term top-line visibility that contract manufacturers in this segment rarely disclose.
The gummy-format supplements category has attracted meaningful capital as food-adjacent wellness brands seek turnkey co-manufacturing partners capable of scaling both nutraceutical and over-the-counter SKUs. TopGum's dual positioning — serving dietary supplement brands while extending into pharmaceutical-grade production — mirrors a broader industry pivot in which ingredient and contract manufacturers are leveraging food-processing infrastructure to capture higher-margin regulated channels. The company's Israeli operations have historically anchored its production base, but the North American market remains the dominant demand driver for premium gummy supplements.
Earlier this month, TopGum completed the acquisition of gummy manufacturing operations in the United States from P&L Developments, establishing a physical U.S. production foothold and an entry point into the domestic pharma sector. The move is consistent with asset-light expansion logic in reverse: rather than licensing capacity, the company is internalizing U.S. output to close the loop between its primary customer geography and its manufacturing network. Management cited geopolitical and logistics headwinds as challenges during the quarter, making the margin expansion to 17% adjusted EBITDA particularly notable.
Looking ahead, TopGum estimates that strategic investments made in recent years could support annual revenues exceeding $250 million in the dietary supplements segment alone, alongside adjusted EBITDA margins above 20%. Whether that trajectory holds will depend on how quickly the newly acquired U.S. facility reaches optimal utilization and whether the company can convert its record backlog into contracted, recurring volume — the key variable for any co-manufacturer competing for long-term brand partnerships. Operators and buyers tracking functional ingredient sourcing and private-label supplement manufacturing should watch TopGum's U.S. integration closely as a bellwether for the broader functional food and beverage manufacturing segment.
For additional context on how gummy-format nutraceuticals are reshaping the dietary supplement supply chain, the Food & Beverage Magazine network — Food & Beverage Magazine — has tracked the category's co-manufacturing consolidation trend through several recent deal cycles.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.
